RxDoctor Payments Data

Kimberly Abdow

Psychiatric/Mental Health · Worcester, MANPI 1003007477

Payments from drug & device makers

$2,621in general payments, 2019–2025

Across 120 payments — averaging $21.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$872
  • Teva Pharmaceuticals USA, Inc.$226
  • Takeda Pharmaceuticals U.S.A., Inc.$224
  • AbbVie$182
  • Alkermes, Inc.$181
  • Vanda Pharmaceuticals Inc.$133
  • plus $804 from 11 others

What the payments were for

  • Food & beverage$2,621100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,621 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$108,342
Medicare patients
178
Services billed
1,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole135$242,971
Invega SustennaPaliperidone Palmitate39$77,777
VraylarCariprazine Hcl30$47,952
TrintellixVortioxetine Hydrobromide60$40,806
Aripiprazole332$28,292
LybalviOlanzapine/Samidorphan Malate14$21,284
VyvanseLisdexamfetamine Dimesylate44$17,185
Chlorpromazine Hcl111$16,265
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine456$15,088
AdderallDextroamphetamine/Amphetamine13$9,296
Paliperidone ErPaliperidone43$8,671
Clonazepam886$8,469
Bupropion XlBupropion Hcl321$7,616
Quetiapine Fumarate362$7,481
Buspirone Hcl373$6,476

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$872$242,971135 claims
Johnson & JohnsonInvega Sustenna$47$77,77739 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse, Adderall$224$67,287117 claims
AbbVieVraylar$182$47,95230 claims
Alkermes, Inc.Lybalvi$181$21,28414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Worcester

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →